The role of combinations of HIV protease inhibitors in the management of persons with HIV infection

Bibliography

• BHIVA GUIDELINES CO-ORDINATING COMMITTEE: Brit- ish HIV Association guidelines for antiretroviral treat-ment of HIV seropositive individuals. Lancet (1997) 349:1086–1092.
   PubMed Web of Science ®Google Scholar
• •Up-to-date reviews of current issues in HIV therapeutics.
   Google Scholar
• CARPENTER CJ, FISCHL MA, HAMMER SM et al: Antiretro- viral therapy for HIV infection in 1997. JAMA (1997) 277: 1962-1969.
   Google Scholar
• •Up-to-date reviews of current issues in HIV therapeutics.
   Google Scholar
• MOYLE GJ: Viral resistance patterns selected by antiret- roviral drugs and their potential to guide treatment choice. Exp. Opin. Invest. Drugs (1997) 6:943–964.
   PubMedGoogle Scholar
• •Up-to-date reviews of current issues in HIV therapeutics.
   Google Scholar
• KEMPF D, RODE R, XU Y et al.: The durability of re- sponse to protease inhibitor therapy is predicted by vi-ral load. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida (1997). Abstract 62.
   Google Scholar
• KOHL NE, EMINI EA, SCHLEIF WA: Active human immu-nodeficiency virus protease is required for viral infec-tivity. Proc. Natl. Acad. Sci. USA (1988) 85:4686–4690.
   PubMed Web of Science ®Google Scholar
• KUMAR GN, RODRIGUES D, BUKO AM et al: Cytochrome P450 metabolism of the 111V-1 protease inhibitor rito-navir (ABT-538) in human liver microsomes. J. Phar-macol. Exp. Ther. (1996) 277:423–431.
   PubMed Web of Science ®Google Scholar
• POLK RE, PAKYZ A, ISRAEL D et al.: Characterization of P450 (CYP) 3A4 activity in patients seropositive for HIV using the erethromycin breath test (ERMBT). Sev-enth Intel-science Conference on Antimicrobial Agents and Chemotherapy. Toronto (1997). Absract A–55.
   Google Scholar
• HSU A, GRANNEMAN GR, WG etal.: Assessment of multi-ple doses of ritonavir on the pharmacokinetics of theophylline. IXth International Conference on AIDS. Vancouver (1996). Abstract.
   Google Scholar
• WOOLLEY J, STUDENBERG S, BOEHLERT C et a/. :Cyto-chrome P450 isoenzyme induction, inhibition and me-tabolism studies with the HIV protease inhibitor 141W94. Seventh Intel-science Conference on Antimicrobial Agents and Chemotherapy. Toronto (1997). Abstract A–60.
   Google Scholar
• MERRY C, BARRY MG, MULCAHY F et al.: Saquinavir pharmacokinetics alone and in combination with rito-navir in HIV-infected patients. AIDS (1997) 11:F29–F33.
   PubMed Web of Science ®Google Scholar
• HSU A, GRANNEMAN GR, JAPOUR A et al.: Evaluation of potential ritonavir and indinavir combination BID regimens. Seventh Intel-science Conference on Antimicro-bial Agents and Chemotherapy. Toronto (1997). Abstract A–57.
   Google Scholar
• KEMPF DJ, MARSH KC, KUMAR G eta].: Pharmacokinetic enhancement of inhibitors of the human immunodefi-ciency virus protease by coadministration with ritona-vir. Antimicrob. Agents Chemother. (1997) 41:654–660.
   Google Scholar
• MCCREA J, BUSS N, STONE J et al.: Indinavir-saquinavir single dose pharmacokinetic study. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC (1997). Abstract 608.
   Google Scholar
• MERRILL DP, MANION DJ, CHOU T-C, HIRSCH MS: An-tagonism between human immunodeficiency virus type-1 protease inhibitors indinavir and saquinavir in vitro. J. Infect. Dis. (1997) 176:265–268.
   PubMed Web of Science ®Google Scholar
• KRAVICK S, SAHAI J, KERR B et al: Protease gene muta-tions and long term follow-up of HIV-infected patients treated with nelfinavir mesylate (NFV) plus saquinavir-soft gel capsule (SQV-SCG). Seventh Intel-sci-ence Conference on Antimicrobial Agents and Chemother-apy. Toronto (1997). Abstract 1–191.
   Google Scholar
• KERR B, LEE C, YUEN G etal.: Overview of in vitro and in vivo drug interaction studies of nelfinavir mesylate (NFV), a new 11IV-1 protease inhibitor. Fourth Confer-ence on Retroviruses and Opportunistic Infections. Washing-ton DC (1997). Abstract 373.
   Google Scholar
• SADLER BM, ERON J, WAKEFORD J et al.: Pharmacokinet-ics of 141W94 and indinavir (IDV) after single-dose co-administration in HIV positive volunteers. Seventh Interscience Conference on Antimicrobial Agents and Che-motherapy. Toronto (1997). Abstract A–56.
   Google Scholar
• ERICKSON JW, BURT SK: Structural mechanisms of HIV drug resistance. Ann. Rev. Pharmacol. Toxicol. (1996) 36:545–571.
   PubMed Web of Science ®Google Scholar
• CONDRA JH, SCHLEIF WA, BLAHY OM et al.: In vivo emergence of 11IV-1 variants resistant to multiple pro-tease inhibitors. Nature (1995) 374:569–571.
   PubMed Web of Science ®Google Scholar
• ••First paper flagging concerns about PI cross-resistance.
   Google Scholar
• ROSE RE, GONG Y-F, GREYTOK JA eta].: Human immu-nodeficiency virus type 1 viral background plays a ma-jor role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA (1996) 93:1648–1653.
   Google Scholar
• FURFINE ES, MASCHERA B, BLAIR ED: Human immuno-deficiency virus resistance to saquinavir is mediated by protease: reduced affinity of mutant protease from saquinavir occurs from increased dissociation rate constants. Fifth International Workshop on HIV Drug Resis-tance. Whistler (1996). Abstract 23.
   Google Scholar
• PAZHANISAMY S, PORTER M, STUVER CM et al.: Kinetic characterization of resistant mutants of HIV protease. Fifth International Workshop on HIV Drug Resistance. Whis-tler (1996). Abstract 26.
   Google Scholar
• CONDRA JH, HOLDER DJ, GRAHAM DJ et al.: Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradica-tion. St Petersburg, Florida (1997). Abstract 47.
   Google Scholar
• LECH WJ, WANG G, YANG YL et al.: In vivo sequence di-versity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistance variants in untreated subjects. J. Virol. (1996) 70:2038–2043.
   PubMed Web of Science ®Google Scholar
• VASUDEVACHARI MB, ZHANG Y-M, IMAMICHI H et al.:Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid sceening procedure fro their detection. Antimicrob. Agents Chemother. (1996) 40:2525–2541.
   Google Scholar
• YAMAGUCHI K, BYRN RA: Clinical isolates of 11IV-1 con-tain few pre-existing proteinase inhibitor resistance-conferring mutations. Biochim. Biophys. Acta (1995) 1253:136–140.
   PubMed Web of Science ®Google Scholar
• WINSLOW DL, STACKS, KING R et al.:Limited sequence diversity of the HIV type-1 protease gene from clinical isolates and in vitro susceptibility to HIV protease in-hibitors. AIDS Res. Hum. Retroviruses (1995) 11:107–113.
   PubMed Web of Science ®Google Scholar
• EL-FARRASH MA, KURODA MJ, KITAZAKI T et al.: Genera-tion and characterization of a human immunodefi-ciency virus type 1 (11IV-1) mutant resistant to an 11IV-1 protease inhibitor. J. Virol (1994) 68:233–239.
   PubMed Web of Science ®Google Scholar
• HO DD, TOYOSHIMA T, MO H et al.: Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C-2 symmetric protease in-hibitor. J. Virol. (1994) 68:2016–2020.
   PubMed Web of Science ®Google Scholar
• KAGEYAMA S, ANDERSON BD, HOESTERY BL et al.: Pro-tein binding of human immunodeficiency virus prote-ase inhibitor KN1-272 and alteration of its in vitro antiretroviral activity in the presence of high concen-trations of proteins. Antimicrob. Agents Chemother. (1994) 38:1107–1111.
   PubMed Web of Science ®Google Scholar
• BILELLO JA, BILELLO PA, RICHARD M et al.: Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum CKI acid glycoprotein. J. Infect. Dis. (1995) 171:546–551.
   PubMed Web of Science ®Google Scholar
• FISCHL MA, RICHMAN DD, FLEXNER C et al.: Phase I study of two formulations and dose schedules of SC-52151, a protease inhibitor. Second Conference on Hu-man Retroviruses and Related Infections. Washington (1995). Abstract 186.
   Google Scholar
• SAHAI J: Risks and synergies from drug interactions. AIDS (1996) 10(Suppl 1):S21–525.
   PubMedGoogle Scholar
• •Review of main drug interactions with Pis.
   Google Scholar
• JACOBSEN H, YASARGIL K, WINSLOW DL et al.: Charac- terization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase in-hibitor Ro31-8959. Virology (1995) 206:527–534.
   PubMed Web of Science ®Google Scholar
• SCHAPIRO JM, WINTERS MA, STEWART F et al.: The effect of high-dose saquinavir on viral load and CD4+ T-cell count in HIV-infected patients. Ann. Intern. Med. (1996) 124:1039–1050.
   PubMed Web of Science ®Google Scholar
• JACOBSEN H, HAENGGI M, OTT M et al: In vivo resis-tance to a human immunodeficiency virus type 1 pro-teinase inhibitor: mutations, kinetics, and frequencies. J. Infect. Dis. (1996) 173:1379–1387.
   PubMed Web of Science ®Google Scholar
• VELLA S, LAZZARIN A, CAROSI G et al.: Saquinavir alone or in combination with zidovudine in previously un-treated patients with advanced HIV infection: a ran-domized Phase I/II controlled trial. Antiviral Ther. (1996) 1:129–140.
   PubMedGoogle Scholar
• CRAIG C, RACE E, SHELDON JG, DUNCAN IB, CAMMACKN: Key amino acid substitutions in HIV proteinase re-main unaltered during increased exposure to saquina-vir (SQV-SGC): results from preliminary clinical trials. Sixth European Conference on Clinical Aspects and Treat-ment of HIV Infection. Hamburg (1997). Abstract 243.
   Google Scholar
• MASCHERA B, TISDALE M, DARBY G et al.: In vitro growth characteristics of 11IV-1 variants with reduced sensitivity to saquinavir explain the appearance of L9OM escape mutant in vivo. Fifth International Work-shop on HIV Drug Resistance. Whistler (1996). Abstract 85.
   Google Scholar
• TOMLINSON PW, CRAIG JC, MOFFATT AR et al.: 11IV-1 from patients in a Phase II clinical trial of the prote-inase inhibitor (PO saquinavir (SQV) taken in combi-nation with RT inhibitors (RTIs) exhibits very little reduced sensitivity to other PIs. AIDS (1996) 10\(Suppl. 2):12, S21.
   Google Scholar
• SHELDON J, CRAIG C, RACE E et al.: Reduced sensitivity to saquinavir (SQV) occurs infrequently, associates only with 48V or 90M and is modest in degree. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC (1997). Abstract 599.
   Google Scholar
• CONDRA JH, HOLDER DJ, SCHLEIF WA et al.: Genetic cor-relates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Vim]. (1996) 70:8270–8276.
   Web of Science ®Google Scholar
• CONDRA JH, SCHLIEF WA, BLAHY OM et al.: Dynamics of acquired 11IV-1 clinical resistance to the protease in-hibitor MK-639. Fourth International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 72.
   Google Scholar
• •Assessment of frequency of cross-resistance with IDV.
   Google Scholar
• MELLORS JW, MCMAHON DK, CHODAKEWITZ JA et al.: Correlation between genotypic evidence of 11IV-1 re-sistance to the protease inhibitor MK-639 and loss of antiviral effect in treated patients. Fourth International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 71.
   Google Scholar
• MOLLA A, KORNEYEVA M, GAO Q et al.: Ordered accu-mulation of mutations in HIV protease confers resis-tance to ritonavir. Nature. Med. (1996) 2:760–766.
   PubMed Web of Science ®Google Scholar
• EASTMAN PS, KELSO R, BOYER E et al.: Loss of suppres-sion of viral replication by ritonavir (ABT-538) is quan-titatively associated with the acquisition of genotypic mutations at codon 82 of the 11IV-1 protease gene. Third Conference on Retroviruses and Opportunistic Infec-tions. Washington DC (1996). Abstract 201.
   Google Scholar
• PAULOUS S, CLAVEL F: Sequential selection by proteaseinhibitors: effects of ritonavir resistance on further se-lection of HIV resistance to saquinavir. Fourth Confer-ence on Retroviruses and Opportunistic Infections. Washington DC (1997). Abstract 598.
   Google Scholar
• MOLLA A, KEMPF D, KORNEYEVA M et al.: Characteriza-tion of the in vivo resistance pathway and pharma-cokinetic properties of ritonavir. Fifth International Workshop on HIV Drug Resistance. Whistler (1996). Abstract
   Google Scholar
• PATICK AK, MO H, MARKOWITZ M et al.: Antiviral andresistance studies of AG1343, an orally bioavailable in-hibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. (1996) 40:292–297.
   PubMed Web of Science ®Google Scholar
• PATICK AK, DURAN M, CAO Y et al.: Genotypic analysisof 11IV-1 variants isolated from patients treated with the protease inhibitor nelfinavir, alone or in combina-tion with d4T or AZT and 3TC. Fourth Conference on Ret-roviruses and Opportunistic Infections. Washington DC (1997). Abstract 10.
   Google Scholar
• PARTELEDIS JA, YAMAGUCHI K, TISDALE M et al.: In vitroselection and characterization of human immunodefi-ciency virus type 1 (111V-1) iolatse with reduced sensi-tivity to hydroxy-ethylamino Sulfonamide inhibitors of 11IV-1 aspatyl protease. J. Vim]. (1995) 69:5228–5235.
   Google Scholar
• PAZHANISAMY S, STUVER CM, CULLINAN A et al.: Kineticcharacterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. (1996) 30:17979–17985.
   Google Scholar
• TISDALE M, MYERS RE, MASCHERA B: Cross-resistanceanalysis of human immunodeficiency virus type 1 variants individually selected for resistance to five dif-ferent protease inhibitors. Antimicrob. Agents Chemo-ther. (1995) 39:1704–1710.
   PubMed Web of Science ®Google Scholar
• HIRSCHEL B, LORENZI P, YERLY S et al.: Escape of vire-mia and rapid development of protease mutations in advanced HIV infection treated with saquinavir and ri-tonavir. Fourth Conference on Retroviruses and Opportun-istic Infections. Washington DC (1997). Abstract 594.
   Google Scholar
• MOLLA A, KORNEYEVA M, CHERNYAVSKIY T et al.: Char-acterization of 11IV-1 protease mutations, compliance and drug concentrations in patients who have HIV RNA rebound on ritonavir/saquinavir. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida (1997). Abstract 83.
   Google Scholar
• PYM AS, CHURCHILL DR, GALPIN sincerely et al.: Pres-ence of mutation at codon90 may predict response to ritonavir/saquinavir combination in HIV seropositive patients pretreated with saquinavir monotherapy. In-ternational Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida (1997). Abstract 84.
   Google Scholar
• ERAKER SD, KIRSCHT JP, BECKER MH: Understandingand improving adherence. Ann. Intern. Med. (1984) 100:258–286.
   PubMed Web of Science ®Google Scholar
• MEICHENBAUM D, TURK DC: Treatment and adherence:terminology, incidence and conceptualisation. In: Fa-cilitating Treatment Adherence. Plenum, New York (1987) :19–39.
   Google Scholar
• HAYNES RB. Determinants of adherence: the disease and the mechanics of treatment. In: Adherence in Healthcare. Haynes RB, Taylor DW, Sackett DC (Eds.), John Hopkins University Press, Baltimore (1979):49–62.
   Google Scholar
• DIMATTEO MR, FRIEDMAN HS: Social Psychology and Medicine. Oelgeschlager, Gunn and Hain, Cambridge, MA (1982):35–58.
   Google Scholar
• CONRAD P: The meaning of medications: another look at adherence. Social Science Medicine (1985) 20(1) :29–37.
   PubMed Web of Science ®Google Scholar
• BECKER MH, MAIMAN LA: Strategies for enhancing ad-herence.j Community Health (1980) 6:113–135.
   PubMedGoogle Scholar
• SINGH N, SQUIER C, SIVEK C et al.: Determinants of ad-herence with antiretroviral therapy in patients with human immunodeficiency virus: prospective assess-ment with implications for enhancing adherence. AIDS Care (1996) 8 (3) :261–269.
   PubMed Web of Science ®Google Scholar
• ELDRED L, WU A, CHAISON RE, MOORE RD: Adherence to antiretroviral therapy in HIV disease. Fourth Confer-ence on Retroviruses and Opportunistic Infections. Washing-ton DC (1997). Abstract 251.
   Google Scholar
• GRIFFITH S: A review of factors associated with patient adherence and the taking of prescribed medicines. Br. J. Gen. Pract. (1990) 40:114–116.
   PubMed Web of Science ®Google Scholar
• EISEN S, MILLER D, WOODWARD R et al.: The effect of prescribed daily dose frequency on patient medica-tion compliance. Ann. Intern. Med. (1990) 150:1881–1884.
   Web of Science ®Google Scholar
• RUDD P, AHMED S, ZACHERY V et al.: Improved compli-ance measures: applications in an ambulatory hyper-tensive trial. Clin. Phrmacol. Ther. (1990) 48:676–685.
   PubMed Web of Science ®Google Scholar
• VANHOVE GF, SCHAPIRO JM, WINTERS MA et al.: Patient compliance and and drug failure in protease inhibitor monotherapy. JAMA (1996) 276:1955–1956.
   PubMed Web of Science ®Google Scholar
• DEEKS S, LOFTUS R, COHEN P et al.: Incidence and pre-dictors of virologic failure to indinavir (IDV) and/or ri-tonavir (RTV) in an urban health clinic. Seventh Interscience Conference on Antimicrobial Agents and Che-motherapy. Toronto (1997). Abstract LB–2.
   Google Scholar
• HAMMER SM, HUGHES MD, SQUIRES K et al.: A con-trolled trial of two nucleoside analogues plus indina-vir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millime-ter or less. New Engl. J. Med. (1997) 337:725–733.
   PubMed Web of Science ®Google Scholar
• BORLEFFS JC, BOUCHER AB, BRAVENBOER B et al.: Saquinavir-soft gelatine capsules versus indinavir as part of AZT and 3TC containing triple therapy. Seventh Intel-science Conference on Antimicrobial Agents and Che-motherapy. Toronto (1997). Abstract 1–92.
   Google Scholar
• POZNIAK A ON BEHALF OF THE SPICE STUDY TEAM: Study of protease inhibitors in combination in Europe (SPICE). Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany (1997). Abstract 209.
   Google Scholar
• ••First clinical data with dual PI therapies.
   Google Scholar
• COHEN C, SUN E, CAMERON D et al.: Ritonavir- saquinavir combination treatment in HIV-infected pa-tients. Sixth Intel-science Conference on Antimicrobial Agents and Chemotherapy New Orleans (1996). Abstract LB7b.
   Google Scholar
• ••First clinical data with dual PI therapies.
   Google Scholar
• FARTHING C, JAPOUR A, COHEN C et al: Cerebrospinal fluid (CSF) and plasma HIV RNA suppression with rito-navir (RIT)-saquinavir (SQV) in protease inhibitor na-ive patients. Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto (1997). Abstract LB3.
   Google Scholar
• ••Reassurance about sanctuary site coverage.
   Google Scholar
• MOYLE GJ, SADLER M, HAWKINS D, BUSS N: Correlation between plasma and CSF viral load in patients on saquinavir containing regimens. Pharmocokinetics (PK) of saquinavir at steady state in CSF and plasma. Sixth European Conference on Clinical Aspects and Treat-ment of HIV Infection. Hamburg, Germany (1997). Abstract 249.
   Google Scholar
• GISLOF EH, COLEBUNDERS R, VAN WANZEELE F etal.: Ef-ficacy and safety of treatment with ritonavir/saquian-vir versus ritonavir/saquinavir/stavudine. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg (1997). Abstract 354.
   Google Scholar
• CLAYTON OB, II: Efficacy and safety of quadruple com-bination therapy in treatment experienced HIV/AIDS patients. Fourth Conference on Retroviruses and Opportun-istic Infections. Washington DC (1997). Abstract 245.
   Google Scholar
• STEINHART CR, GEORGE SA, MANN RD: 'Salvage ther-apy' using the combination of ritonavir and saquina-vir in patients with advanced HIV infection. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC (1997). Abstract 199.
   Google Scholar
• SAMPSON M, TORRES RA, STEIN AJ et al.: Ritonavir-Saquinavir combination treatment in protease inhibi-tor experienced patients with advanced HIV disease. Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto (1997). Abstract 1–104.
   Google Scholar
• DEEKS S, GRANT R, HORTON C et al.: Virologic effect of ritonavir (RTV) plus saquinavir (SQV) in subjects who have failed on indinavir (IDV). Seventh Intel-science Con-ference on Antimicrobial Agents and Chemotherapy. To-ronto (1997). Abstract 1–205.
   Google Scholar
• MILLER V, HERTOGS K, DE BETHUNE M-P et al.: Inci-dence of 111V-1 resistance and cross-resistance to pro-tease inhibitors after indinavir failure: impact on subsequent ritonavir/saquinavir combination ther-apy. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida (1997). Abstract 81.
   Google Scholar
• HENRY K, KANE E, MELROSE H et al: Experience with a ritonavir/saquinavir based regimen for the treatment of HIV-infection in subjects developing increased viral loads while receiving nelfinavir. Seventh Intel-science Conference on Antimicrobial Agents and Chemotherapy. Toronto (1997). Abstract 1–204.
   Google Scholar
• SAMPSON MS, BARR MR, TORRES RA, HALL G: Viral load changes in nelfinavir treated patients switched to a second protease inhibitor after loss of viral suppres-sion. Seventh Intel-science Conference on Antimicrobial Agents and Chemotherapy. Toronto (1997). Abstract LB–5.
   Google Scholar
• BODSWORTH NJ, HEAPS M, GOSLING D et al.: Efficacy of indinavir (IDV) and ritonavir (IITV) in patients pre-treated with saquinavir. Seventh International Antiviral Symposium. Sydney (1997).
   Google Scholar
• BERGER DS, BUCHER G, DELANEY K et al.: Further re-duction in plasma HIV load in patients with advanced AIDS when a second protease inhibitor was added to triple drug combination therapy. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC (1997). Abstract 244.
   Google Scholar
• ANGEL JB, PARATO K, KUMAR A et al.: Rapid improve-ment in cell mediated immune function with initiation of ritonavir plus saquinavir in HIV immune deficiency. Fourth Conference on Retroviruses and Opportunistic Infec-tions. Washington DC (1997). Abstract 33.
   Google Scholar
• LOHMEYER J, SEELHORST J, FRIESE G eta].: Combinationuse of nelfinavir and saquinavir in a bid schedule as rescue therapy in advanced HIV infection. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg (1997). Abstract 925.
   Google Scholar
• •SQV-NFV bid dosing.
   Google Scholar
• LAL R, HSU A, CHEN P et al.: Single dose pharmacokinet-ics of ABT-378 in combination with ritonavir. Seventh Intel-science Conference on Antimicrobial Agents and Che-motherapy Toronto (1997). Abstract 1–194.
   Google Scholar
• CARRILLO A, SHAM H, NORBECK D et al.: Selection and analysis of 111V-1 variants with increased resistance to ABT-378, a novel protease inhibitor. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC (1997). Abstract 209.
   Google Scholar
• ADKINS JC, FAULDS D: 141W94. Drugs (In Press.)
   Google Scholar
• CARR A, SAMARAS K, BURTON S et al.: A syndrome of pe-ripheral lipodystrophy (LD), hyperlipidaemia and in-sulin resistance due to HIV protease inhibitors (P1s). Fifth Conference on Retroviruses and Opportunistic Infec-tions. Chicago (1998). Abstract 410.
   Google Scholar